vfend 200 mg film-coated tablets
pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 200 mg - voriconazole - voriconazole - treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei),- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
vfend 200 mg powder for solution for infusion
pfizer pfe pharmaceuticals israel ltd - voriconazole - powder for solution for infusion - voriconazole 200 mg/vial - voriconazole - voriconazole - treatment of :- invasive aspergillosis fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
vfend 200 mg powder for solution for infusion
pfizer pfe pharmaceuticals israel ltd - voriconazole - powder for solution for infusion - voriconazole 200 mg/vial - voriconazole - voriconazole - treatment of :- invasive aspergillosis fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
vfend 40 mgml powder for oral suspension
pfizer pfe pharmaceuticals israel ltd - voriconazole - powder for suspension - voriconazole 40 mg/ml - voriconazole - voriconazole - treatment of : - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
cytosar 1 g.
pfizer pfe pharmaceuticals israel ltd - cytarabine - powder for solution for injection - cytarabine 1 g/vial - cytarabine - cytarabine - induction and maintenance of remission in acute myelocytic leukemia of adults and children. treatment of other leukemias.
voriconazole mylan
mcdermott laboratories ltd t/a gerard laboratories - voriconazole - film coated tablet - 200 milligram - voriconazole
voriconazole pfizer 50 mg film-coated tablets
pfizer healthcare ireland - voriconazole - film-coated tablet - 50 milligram(s) - triazole derivatives; voriconazole
voriconazole pfizer 200 mg powder for solution for infusion
pfizer healthcare ireland - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole
voriconazole pfizer 40 mg/ml powder for oral suspension
pfizer healthcare ireland - voriconazole - powder for oral suspension - 40 milligram(s)/millilitre - triazole derivatives; voriconazole
voriconazole pfizer 200 mg film-coated tablets
pfizer healthcare ireland - voriconazole - film-coated tablet - 200 milligram(s) - triazole derivatives; voriconazole